Back to Journals » OncoTargets and Therapy » Volume 10
Original Research
VTD-melphalan is well tolerated and results in very high rates of stringent CR and MRD-negative status in multiple myeloma
Total article views | HTML views | PDF downloads | Totals | ||
---|---|---|---|---|---|
8,442 | Dovepress* | 7,345+ | 1,416 | 8,761 | |
PubMed Central* | 1,097 | 282 | 1,379 | ||
Totals | 8,442 | 1,698 | 10,140 | ||
*Since 6 January 2017 |
Total mentioned | Delicious | Others | |||
---|---|---|---|---|---|
4 | 0 | 0 | 0 | 2 | 2 |
View citations on PubMed Central and Google Scholar